- Home
- UPST vs CRNX Comparison
UPST vs CRNX Comparison
Compare UPST & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | CRNX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UPST | CRNX |
|---|---|---|
| Price | $47.32 | $54.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $59.96 | ★ $73.70 |
| AVG Volume (30 Days) | ★ 4.9M | 1.6M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $997,748,000.00 | $1,535,000.00 |
| Revenue This Year | $56.14 | $425.41 |
| Revenue Next Year | $22.99 | $943.30 |
| P/E Ratio | $183.61 | ★ N/A |
| Revenue Growth | ★ 64.93 | 47.74 |
| 52 Week Low | $31.40 | $24.10 |
| 52 Week High | $96.43 | $57.99 |
Technical Indicators
Market Signals| Indicator | UPST | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 65.71 |
| Support Level | $43.06 | $51.61 |
| Resistance Level | $51.53 | $56.13 |
| Average True Range (ATR) | 2.43 | 2.78 |
| MACD | -0.16 | 0.64 |
| Stochastic Oscillator | 44.47 | 76.73 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.